BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Other Current Assets
Current assets not reported separately, such as prepaid expenses.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 152.8% from a year ago
Other current assets stood at $14.08M at the end of Q1 FY2026, up 152.8% from a year earlier and up 3747.9% from the prior quarter.
Context
- Other current assets amounted to 3.4% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
- Other current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +152.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- (386K) USD
- Year-over-year change
- —
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (386K) | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Assets vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +152.8% is the 3rd highest of 9, against a peer median of -30.8%.
- Other current assets amounts to 3.4% of total assets for BBOT, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $19.53M USD | +38.9% | +10.4% | 7.7% | |
| Sep 2026 | $15.16M USD | +3442.5% | +14.1% | 1.5% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $14.08M USD | +152.8% | — | 3.4% |
SEPNSepterna, Inc. | Sep 2026 | $9.86M USD | +2448.8% | +78.1% | 1.6% |
| Mar 2026 | $8.44M USD | -35.4% | +44.1% | 2.8% | |
| Mar 2026 | $3.91M USD | -26.2% | +1.6% | 1.2% | |
| Sep 2026 | $0 USD | -100.0% | -11.2% | 0.0% | |
| Jun 2026 | $0 USD | -100.0% | -0.7% | 0.0% | |
| Aug 2026 | $0 USD | -100.0% | +14.2% | 0.0% | |
| Mar 2026 | CHF 0 CHF | — | +65.6% | 0.0% | |
| Peer median (excluding BBOT) | — | -30.8% | +14.1% | 1.2% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.